How Well Does Galcanezumab Work for Migraines in Real-World Spanish Patients?
Galcanezumab reduced migraine days and disability in 2,592 Spanish patients, with 60–77% staying on treatment at one year.
Quick Facts
What This Study Found
Across 29 real-world Spanish studies, galcanezumab showed consistent reductions in monthly migraine days and monthly headache days. Disability scores (MIDAS) and headache impact scores (HIT-6) also improved.
12-month persistence ranged from 59.8% to 76.8%, meaning about 6 to 8 out of 10 patients stuck with treatment for a full year. Serious adverse events were rare. One study reported high patient satisfaction. No study included health-related quality of life data.
Key Numbers
- 29 publications included
- 2,592 Spanish adult patients
- 12-month persistence: 59.8% to 76.8%
- Significant reductions in monthly migraine days and monthly headache days
- Improvements in MIDAS disability and HIT-6 impact scores
- Serious adverse events: rare
How They Did This
This was a systematic literature review following PRISMA and Cochrane guidelines. Researchers searched for observational studies on galcanezumab in Spanish patients, published from August 2020 to August 2023, in English or Spanish. They included 29 publications covering 2,592 adult patients.
Why This Research Matters
Clinical trials show drugs work under controlled conditions. Real-world data shows how they perform in everyday practice, with typical patients who often have other health conditions, use other medications, and may not be as strictly monitored. This review confirms galcanezumab's benefits translate outside the trial setting in a large Mediterranean population.
The Bigger Picture
Clinical trials show drugs work under ideal conditions. This large real-world review confirms galcanezumab's benefits translate to everyday Spanish clinical practice with typical patients.
What This Study Doesn't Tell Us
This is a review of observational studies with no control groups or randomization. Publication bias may favor positive results. No study included quality-of-life measures, which limits understanding of the full patient experience. The data is from Spain only and may not generalize to all populations.
Questions This Raises
- ?Why do 23–40% of patients discontinue within a year?
- ?How does galcanezumab compare to other CGRP antibodies in real-world settings?
Trust & Context
- Key Stat:
- 2,592 patients across 29 studies One of the largest real-world evidence reviews for galcanezumab in a single-country population
- Evidence Grade:
- Rated moderate: systematic review following PRISMA guidelines, but includes only observational studies without control groups.
- Study Age:
- Published in 2024, reviewing studies from August 2020 to August 2023. Covers the first three years of real-world galcanezumab use in Spain.
- Original Title:
- Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review.
- Published In:
- Frontiers in neurology, 15, 1502475 (2024)
- Authors:
- Pozo-Rosich, Patricia(5), García-Azorín, David(3), Díaz-Cerezo, Silvia(2), Fernández-Montoya, Julia, de Paz, Héctor David, Núñez, Mercedes
- Database ID:
- RPEP-09086
Evidence Hierarchy
Frequently Asked Questions
How effective is galcanezumab in real-world use?
In over 2,500 Spanish patients, it consistently reduced monthly migraine days, headache days, and disability scores, matching clinical trial results.
How long do patients stay on galcanezumab?
Between 60% and 77% of patients remained on treatment at one year, with most discontinuations due to insufficient response rather than side effects.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09086APA
Pozo-Rosich, Patricia; García-Azorín, David; Díaz-Cerezo, Silvia; Fernández-Montoya, Julia; de Paz, Héctor David; Núñez, Mercedes. (2024). Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review.. Frontiers in neurology, 15, 1502475. https://doi.org/10.3389/fneur.2024.1502475
MLA
Pozo-Rosich, Patricia, et al. "Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review.." Frontiers in neurology, 2024. https://doi.org/10.3389/fneur.2024.1502475
RethinkPeptides
RethinkPeptides Research Database. "Real-world experience of galcanezumab in the prevention of m..." RPEP-09086. Retrieved from https://rethinkpeptides.com/research/pozo-rosich-2024-realworld-experience-of-galcanezumab
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.